What is Cometriq (cabozantinib) for?
Cometriq (cabozantinib) is a cancer medicine indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC)1,2.
How does Cometriq (cabozantinib) work?
The active substance in Cometriq, cabozantinib, is a tyrosine kinase inhibitor. It blocks the activity of enzymes known as tyrosine kinases. These enzymes can be found in certain receptors in cancer cells where they activate several processes including cell division and the growth of new blood vessels to supply the cancer. By blocking the activity of these receptors in cancer cells, the medicine reduces the growth and spread of the cancer1.
Is Cometriq (cabozantinib) approved?
Cometriq (cabozantinib) was approved for progressive, metastatic medullary thyroid cancer (MTC)1,2 by:
- FDA (USA) on November 29, 20124
- EMA (EU) on March 26, 20141
How is Cometriq (cabozantinib) taken?
The standard dosage is:
Patients should not eat for at least 2 hours before and at least 1 hour after taking it1,2.
Warning: Cabozantinib tablets should not be substituted with cabozantinib capsules.
It can be expected that a majority of patients will require one or more dose adjustments (reduction and/or interruption) due to toxicity. When dose reduction is necessary, it is recommended to reduce to 100 mg daily, taken as one 80 mg capsule and one 20 mg capsule, and then to 60 mg daily, taken as three 20 mg capsules2,3.
Complete information about Cometriq (cabozantinib) dosage and administration can be found in the resources section.
Note: Consult your treating doctor for personalised dosing.
Are there any known side-effects of Cometriq (cabozantinib)?
There are some warnings and precautions associated with Cometriq (cabozantinib). Two of these are the occurrence of gastrointestinal perforations and fistulas, and haemorrhage. See the prescribing information for a complete list3,2.